FDA Fast Tracks Antibody-Drug Conjugate for Ovarian, Fallopian Tube, Primary Peritoneal Cancers

BioNTech SE and Duality Biologics’ next-generation antibody-drug conjugate is being evaluated for patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer previously administered one to three systemic treatment regimens.

Source link
#FDA #Fast #Tracks #AntibodyDrug #Conjugate #Ovarian #Fallopian #Tube #Primary #Peritoneal #Cancers